Intel (INTC) (TSCO) (CLB) (SABA) (ALTH) Downgraded

Intel (NASDAQ: INTC), Tractor Supply Co. (NASDAQ: TSCO), Core Labs (NYSE: CLB), Saba Software (NASDAQ: SABA) and Allos Therapeutics Incorporated (NASDAQ: ALTH) downgraded by analysts.

Craig Hallum downgraded Saba Software (SABA) from a “buy” rating to a “hold” rating.

Feltl & Co. downgraded Tractor Supply Co. (TSCO) from a “buy” rating to a “hold” rating. They have a price target of $67.95 on the company, down from $69.75.

JMP Securities downgraded Allos Therapeutics Incorporated (ALTH) from an “outperform” rating to a “market perform” rating.

RBC Capital downgraded Core Labs (CLB) from an “outperform” rating to a “sector perform” rating. They have a price target of $117.00 on the company, up from $110.00.

Nomura downgraded Intel (INTC) from a “neutral” rating to a “reduce” rating.

Price Targets on (ALTH) (APEI) (ARX) (CE) (CLWR) Updated

Analysts updated price targets on Allos Therapeutics Incorporated (NASDAQ: ALTH), American Public Education (NASDAQ: APEI), Aeroflex Holding Corp. (NYSE: ARX), Celanese Co. (NYSE: CE) and Clearwire (NASDAQ: CLWR).

Citigroup (NYSE:C) cut their price target on Allos Therapeutics Incorporated (ALTH) from $7.00 to $5.00. They have a “buy” rating on the stock.

RBC Capital raised their price target on American Public Education (APEI) from $42.00 to $50.00. They have an “outperform” rating on the company.

Needham & Company raised their price target on Aeroflex Holding Corp. (ARX) from $20.00 to $22.00. They have a “buy” rating on the company.

Citigroup raised their price target on Celanese Co. (CE) from $59.00 to $63.00. They have a “buy” rating on the company.

Citigroup cut their price target on Clearwire (CLWR) from $7.00 to $6.00. They have a “reduce” rating on the company.

Ratings on (GNET) (ALTH) (NVDA) (AHII) Downgraded

Ratings on Global Traffic Network (NASDAQ:GNET), Allos Therapeutics (NASDAQ:ALTH), NVIDIA (NASDAQ:NVDA) and Animal Health Intl (NASDAQ:AHII) were downgraded by analysts.

Feltl & Co. downgraded Global Traffic Network (GNET) from a "Strong Buy" rating to a "Buy" rating. They lowered their price target from $15.50 to $14 on the company.

MP Advisors downgraded Allos Therapeutics (ALTH) from an "Outperform" rating to a "Market Perform" rating. They lowered their price target on the company from $7 to $3.50.

Needham downgraded NVIDIA (NVDA) from a "Buy" rating to a "Hold" rating.

Robert W. Baird downgraded Animal Health International (AHII) from an "Outperform" to "Neutral." They have a price target of $4.00 on the company.

Coverage on (ALTH) (APTS) (BRE) (CHRW) (CLP) Initiated

Coverage on shares Allos Therapeutics Incorporated (NASDAQ: ALTH), Preferred Apt. Communities (NASDAQ: APTS), Bre Properties Inc. (NYSE: BRE), C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) and Colonial Properties (NYSE: CLP) was initiated by analysts.

Brean Murray initiated coverage on Allos Therapeutics Incorporated (ALTH). They placed a “buy” rating and a price target of $6.00 on the company.

Wunderlich initiated coverage on Preferred Apt. Communities (APTS). They placed a “buy” rating and a price target of $12.00 on the company.

Wunderlich initiated coverage on Bre Properties Inc. (BRE). They placed a “buy” rating and a price target of $54.00 on the company.

Sanford C. Bernstein initiated coverage on C.H. Robinson Worldwide, Inc. (CHRW). They placed a “market perform” rating and a price target of $89.00 on the company.

Wunderlich initiated coverage on Colonial Properties (CLP). They placed a “hold” rating and a price target of $21.00 on the company.

Ratings on (AIXG) (ALTH) (BCON) (ATHR) (BMY) Downgraded

Ratings on shares of Aixtron AG (NASDAQ: AIXG), Allos Therapeutics Incorporated (NASDAQ: ALTH), Beacon Power Corp. (NASDAQ: BCON), Atheros Communications (NASDAQ: ATHR) and Bristol Myers Squibb Co. (NYSE: BMY) were downgraded by analysts.

Canaccord Genuity downgraded Aixtron AG (AIXG) from a “hold” rating to a “sell” rating.

Needham & Company downgraded Allos Therapeutics Incorporated (ALTH) from a “buy” rating to a “hold” rating.

FBR Capital downgraded Atheros Communications (ATHR) from an “outperform” rating to a “market perform” rating. They have a price target of $45.00 on the company.

Ardour Capital downgraded Beacon Power Corp. (BCON) from an “accumulate” rating to a “hold” rating. They have a price target $1.50 on the company, down from $3.00.

Goldman Sachs (NYSE:GS) downgraded Bristol Myers Squibb Co. (BMY) to a “neutral” rating. They have a price target of $77.00 on the company.

Price Targets on (ALTH) (APEI) (BBRG) (CE) (CPLP) Updated

Price targets on shares of Allos Therapeutics Incorporated (NASDAQ: ALTH), American Public Education (NASDAQ: APEI), Bravio Brio (NASDAQ: BBRG), Celanese Co. (NYSE: CE) and Capital Product Partners L.P. (NASDAQ: CPLP) were updated by analysts.

JPMorgan Chase & Co. (NYSE:JPM) cut their price target on Allos Therapeutics Incorporated (ALTH) from $10.00 to $8.00. They have an “overweight” rating on the company.

Sterne Agee raised their price target on American Public Education (APEI) from $43.00 to $45.00. They have a “buy” rating on the company.

Morgan Keegan raised their price target on Bravio Brio (BBRG) from $22.00 to $23.00. They have an “outperform” rating on the company.

Bank of America (NYSE:BAC) raised their price target on Celanese Co. (CE) from $56.00 to $60.00. They have a “buy” rating on the company.

Deutsche Bank (NYSE:DB) raised their price target on Capital Product Partners L.P. (CPLP) from $9.00 to $10.00. They have a “hold” rating on the company.

FOLOTYN Sales Will Continue to Drive Allos Therapeutics (NASDAQ:ALTH)

In 2011, FOLOTYN sales will continue to be the main catalyst for Allos Therapeutics (NASDAQ:ALTH), which should bode well for the company.

Needham said, "Looking into 2011, we believe FOLOTYN sales will continue to be the main driver of the stock, and we expect the recent clinical data, new dosing adjustment strategy, and the permanent J-code to facilitate the adoption of FOLOTYN in r/r PTCL...We believe FOLOTYN, the only approved drug to date for r/r PTCL, is uniquely positioned and may establish itself as the standard of treatment for r/r PTCL. In the long-term, label expansion represents the long-term growth opportunity for FOLOTYN and the Company."

Needham & Company reiterates a "Buy" rating on Allos Therapeutics, which closed Wednesday at $4.46, down $0.06, or 1.33 percent. Needham has a price target of $8 on Allos.

A Look at AVEO (Nasdaq:AVEO), ZIOPHARM (NASDAQ:ZIOP), Exelixis (Nasdaq:EXEL), Allos (NASDAQ:ALTH), Synta (NASDAQ:SNTA) and Immunogen (Nasdaq:IMGN)

AVEO Pharmaceuticals (Nasdaq:AVEO), ZIOPHARM Oncology (NASDAQ:ZIOP), Exelixis (Nasdaq:EXEL), Allos Therapeutics(NASDAQ:ALTH), Synta Pharmaceuticals (NASDAQ:SNTA) and Immunogen (Nasdaq:IMGN) were commented on by Canaccord Genuity, as they took a look at the Biotech small cap sector.

Canaccord's take on the companies:

"AVEO Pharmaceuticals (BUY) Investment recommendation: We maintain our BUY rating going into top-line results from the Phase III TIVO-1 trial evaluating tivozanib for treatment of renal cell carcinoma."

"ZIOPHARM Oncology (BUY) Investment recommendation: On the potential of a diversified clinical oncology pipeline, we remain long-term buyers of ZIOP shares.

"Synta Pharmaceuticals (HOLD) Investment recommendation: We maintain our HOLD rating based on lack of meaningful clinical data supporting the potential of STA-9090 for treatment of oncologic indications.

"Immunogen (Buy-rated) Investment recommendation: Although approaching our DCF-based $10 price target, we continue to remain positively inclined on IMGN shares given perceived potential of Roche’s trastuzumab-DM1 (T-DM1) in metastatic breast cancer (MBC).

"Exelixis (HOLD-rated) Investment recommendation: On our view that share value more than fully reflects the risk/reward for potential of XL184 in metastatic prostate cancer, we maintain our HOLD rating.

"Allos Therapeutics (HOLD) Investment recommendation: We maintain our HOLD rating on ALTH given our view that shares adequately reflect potential of Folotyn in the peripheral T cell lymphoma (PTCL) treatment market.

Aveo closed Tuesday at $14.61, down $0.06, or 0.41 percent. Ziopharm closed at $4.71, down $0.12, or 2.48 percent. Exelixis closed up at $8.85, gaining $0.07, or 0.80 percent. Allos closed at $4.62, up $0.01, or 0.22 percent. Synta closed at $6.37, up $0.04, or 0.63 percent. Immunogen ended the session at $9.70, down $0.02, or 0.21 percent.